What up? DXB- no other way.., page-8

Thanks Prestonian. Came back for the party! The transcript is quite interesting. There is another section that address their FSGS program. Their Ph3 study won't start till year end. Quite some time away. Perhaps the FDA has asked them to do some other work before commencing Ph3. Safety is still the question mark with Sparsanten. Ph3 will be all revealing. There is still the issue of how clinicians will view using Sparsentan in place of Ibesartan if the trial shows superiority to Ibsesartan. Blood pressure control is critical in all chronic kidney disease, and most patients will be on an ARB or and ACEi so they would like have to stop it and start Sparsentan in FSGS. Safety of the combination to justify continuing the ARB or ACEi would have to be demonstrated in a large post marketing safety study. I still believe the add on option PPG offers on the background of an ARB (or even ACEi) is clincially advantageous and likely beneficial for many patients with CKD with proteinuria.

Either way. This company is ridiculously priced at the moment. Look at PYC. If that can command a market cap of $100M, then DXB surely should be at least $30-40M!!